LEXX
Lexaria Bioscience Corp.NASDAQHealthcare$1.06+1.92%ClosedMarket Cap: $20.5M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
4.61
P/S
39.26
EV/EBITDA
-1.52
DCF Value
$-1.62
FCF Yield
-42.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
84.9%
Operating Margin
-2021.0%
Net Margin
-2067.7%
ROE
-209.6%
ROA
-178.4%
ROIC
-228.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 2026 | $0.00 | -Infinity% | $-1.6M | $-1.6M | $-0.07 | — |
| Q4 2025 | $174.0K | 87.7% | $-2.5M | $-2.7M | $-0.14 | — |
| FY 2025 | $705.9K | 83.2% | $-11.6M | $-11.9M | $-0.66 | — |
| Q3 2025 | $174.0K | 91.1% | $-3.8M | $-3.8M | $-0.21 | — |
| Q2 2025 | $174.0K | 89.8% | $-2.8M | $-2.7M | $-0.15 | — |
| Q1 2025 | $183.9K | 80.5% | $-2.6M | $-2.7M | $-0.16 | — |
| Q4 2024 | $84.0K | 80.5% | $-2.2M | $-2.2M | $-0.17 | — |
| FY 2024 | $464.3K | 82.6% | $-5.7M | $-5.8M | $-0.47 | — |
| Q3 2024 | $84.0K | 82.1% | $-1.7M | $-1.8M | $-0.13 | — |
| Q2 2024 | $145.0K | 89.0% | $-668.0K | $-649.5K | $-0.06 | — |
| Q1 2024 | $151.3K | 70.6% | $-1.1M | $-1.2M | $-0.13 | — |
| Q4 2023 | $30.7K | -82.7% | $-1.1M | $-1.2M | $-0.12 | — |